All In Biotech

Drug Trial Radar · NCT00210964

Ceftobiprole in Hospital Acquired Pneumonia

A Phase III Randomized Double-Blind Study Of Ceftobiprole Versus Linezolid Plus Ceftazidime In The Treatment Of Nosocomial Pneumonia

Last checked: Nov 19, 2026Latest source record: Sep 3, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 781 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

781

Actual

Start

Apr 2005

Primary completion

May 2007

Study completion May 2007

Sponsor

Lead sponsor
Basilea PharmaceuticaIndustry
Sponsor type
Industry
First posted
Sep 21, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril (the water-soluble prodrug \[form\] of ceftobiprole) referred to as ceftobiprole versus a comparator in the treatment of patients with nosocomial pneumonia.

Conditions

  • Pneumonia

Interventions

  • ceftobiprole plus placeboDrug

    ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days

  • linezolid plus ceftazidimeDrug

    linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical cure rate (the ratio of the number of clinically cured patients to the total number of patients in the population)Time frame: 7 to 14 days after the end-of-therapy (EOT)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.